Literature DB >> 3251178

Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody.

M V Pimm1, H F Fells, A C Perkins, R W Baldwin.   

Abstract

Studies have been carried out in mice to examine by gamma camera imaging and dissection analysis the biodistribution of 131I- and 111In-labelled avidin and streptavidin. This has included mice with human tumour xenografts pre-targetted with biotinylated anti-tumour monoclonal antibody. Both iodine-labelled avidin and streptavidin were cleared rapidly from the circulation particularly to kidneys, which showed prolonged retention of the tracer. Similar distribution was seen with 111In-labelled preparations, although here tracer also accumulated in the liver. Radiolabelled preparations could form complexes in vitro with a biotinylated monoclonal antibody. This biotinylated antibody, following radioiodine labelling, localized in xenografts of a human osteosarcoma. When xenografted mice were injected with biotinylated antibody followed by 111In-labelled avidin, levels of tracer per gram of tumour tissue were four times higher than those in non-pretreated mice. However, there was still marked liver and kidney uptake of tracer and, since this dominated the images, tumours were not visualized by scintigraphy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3251178     DOI: 10.1097/00006231-198811000-00010

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  In vivo assembly of nanoparticle components to improve targeted cancer imaging.

Authors:  Steven D Perrault; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  An overview of radioimmunotherapy.

Authors:  A Maraveyas; A A Epenetos
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 4.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

5.  Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties.

Authors:  Antonio Verdoliva; Piero Bellofiore; Vincenzo Rivieccio; Sergio Catello; Maurizio Colombo; Claudio Albertoni; Antonio Rosi; Barbara Leoni; Anna Maria Anastasi; Rita De Santis
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

Review 6.  Pretargeting for imaging and therapy in oncological nuclear medicine.

Authors:  Clément Bailly; Caroline Bodet-Milin; Caroline Rousseau; Alain Faivre-Chauvet; Françoise Kraeber-Bodéré; Jacques Barbet
Journal:  EJNMMI Radiopharm Chem       Date:  2017-06-06

Review 7.  Therapeutic Applications of Pretargeting.

Authors:  Marjolein Verhoeven; Yann Seimbille; Simone U Dalm
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.